glutarimide has been researched along with Multiple Myeloma in 2 studies
*Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamchik, M; Bubyrev, A; Bunev, A; Hartmann, MD; Heim, C; Krasavin, M; Maiwald, S; Zhmurov, P; Zhukovsky, D | 1 |
| Baculi, F; Carmel, G; Condroski, K; Correa, M; Crea, T; Hansen, JD; Hickman, M; LeBrun, L; Liu, W; Lu, CC; Lu, G; Mahmoudi, A; Man, HW; Muller, G; Ruchelman, A; Vocanson, F; Zhang, W | 1 |
2 other study(ies) available for glutarimide and Multiple Myeloma
| Article | Year |
|---|---|
Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Humans; Multiple Myeloma; Peptide Hydrolases; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases | 2023 |
Protein Degradation via CRL4
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Chemistry Techniques, Synthetic; Drug Evaluation, Preclinical; Humans; Ikaros Transcription Factor; Molecular Docking Simulation; Multiple Myeloma; Peptide Hydrolases; Peptide Termination Factors; Phthalimides; Piperidones; Proteolysis; Quantitative Structure-Activity Relationship; Ubiquitin-Protein Ligases | 2018 |